Published Thu, 13 Aug 2020 12:24:41 -0400 on Seeking Alpha
Seeking AlphaDividend Ideas | Healthcare Why Pfizer's 4% Yield Is Your Best Covid-19 Vaccine PlayAug. 13, 2020 12:24 PM ET|| About: Pfizer Inc. (PFE), Includes: ARCT, AZN, AZNCF, BNTX, DVAX, INO, JNJ, MRK, MRNA, MYL, NVAXby: Robert & Sam KovacsRobert & Sam Kovacs Long only, dividend investing, dividend growth investingSummaryI demonstrate why Pfizer is the best choice for dividend investors playing the Covid-19 vaccine theme.
The worries about a dividend decrease from the Upjohn spinoff are overblown.
What will be left will be a lean, high growth, biopharmaceutical company.
Written by Robert Kovacs
Back in May, I wrote an article in which I suggested that “with or without a Covid-19 vaccine”, Pfizer (PFE) was a buy.
Since then the stock has dropped 15% and climbed back to the price it was a quarter ago. Pfizer is currently trading at $37.79 and yields 4.02%.
Source: Open Domain
Quite a lot can happen in 3 months. And quite a lot has happened. For one, Mylan (MYL) shareholders overwhelmingly approved the Upjohn-Mylan merger which is expected to close by the end of the year.
On the Covid-19 vaccine front –where Pfizer collaborates with BioNTech (BNTX), the vaccine which has entered phase 3 clinical trials is showing promise. A lot is expected from vaccine frontrunners such as Pfizer, Moderna (MRNA) & AstraZeneca (AZN).
Back in May, I believed making bets on Covid-19 programs was too early. Yet as time has passed, it has come obvious to me that not only Pfizer is a great pick with or without the vaccine, it is a frontrunner, and as likely as any of the other top candidates to have a winner. While we aren’t out of the woods yet, more positive news keeps coming. The least I can say is that I am cautiously optimistic about the whole thing.
Our MAD Scores give PFE a Dividend Strength score of 89 and a Stock Strength score of 69.
Before going through Pfizer’s... Read more
|Stock name||Last trade||P/E||Earnings/Share||Dividend/Share||Dividend yield|
|JOHNSON & JOHNSON||130.43||21.6||6.03||3.80||2.93|
|MERCK & CO||83.31||23.3||3.57||2.20||2.69|
Older articles featuring Johnson & Johnson (JNJ):Johnson & Johnson: A Top Dividend Stock for 2021 & Beyond
Roche Is A Suitable Addition To Diversified Dividend Growth Portfolios
31 December Dividend Stocks Billionaires Hold
Revisiting Yield Channel Charts
Nicholas Ward's Dividend Growth Portfolio: November 2020 Review
Dividend Champion And Contender Highlights: Week Of December 6
Johnson & Johnson: 3 Reasons to Check Out This Dividend Giant Now
All Weather Dividends: 10 Value Buys And 5 Overvalued Sells To End 2020
Of 56 Kiplinger Outstanding Dividend Stocks, 11 Show Sweetness For December
Vanguard High Dividend Yield ETF: Rotation From Growth Into Value Stocks Should Boost Investor Appetite For This ETF